Navigation Links
Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy
Date:5/13/2009

sting treatments."

About Circassia

Circassia is a specialty biopharmaceutical company focused on the field of allergy. The company's range of allergy therapeutics utilizes its proprietary T-cell epitope desensitization technology, ToleroMune. Circassia's products offer potential major clinical benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe, and the current treatment market is approximately $12 billion per year. ToleroMune technology has additional potential regulatory and supply benefits for Circassia. Its state-of-the-art manufacturing fits with changes in the European regulatory environment, where authorities are increasingly treating allergen immunotherapies as pharmaceutical products, and eliminating the batch-to-batch potency variability that is an intrinsic feature of many currrent treatments. Circassia has a highly experienced management team with a proven track record in product development and commercialization. Having successfully completed two fundraising rounds the company is backed by a syndicate of world-class venture capital and institutional investors, including Imperial Innovations, Lansdowne Partners, Goldman Sachs and Invesco Perpetual.

    For more information please visithttp://www.circassia.co.uk.

    Contacts:
    Steve Harris
    Rob Budge
    CEO RJB Communications
    Circassia
    Tel: +44(0)1865-760969
    Tel: +44(0)1865-784574


'/>"/>
SOURCE Circassia Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Circassias Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
2. Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
3. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
4. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
5. Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development
6. Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent
7. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
8. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
9. AFFiRiS Begins Development of a Parkinsons Vaccine
10. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
11. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  A new analysis of ... D 2015 enrollment data shows that 81 percent of ... access and extra discounts at certain pharmacies. The findings ... "Preferred pharmacy plans are now the foundation of Medicare ...
(Date:1/23/2015)... , Jan. 23, 2015 /PRNewswire/-- Harwood Feffer LLP ( ... of directors of Advaxis, Inc. ("Advaxis" or the "Company") ... has breached its fiduciary duties to shareholders. ... an investing website reporting that Advaxis had misrepresented the ...
(Date:1/23/2015)... 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the ... Lixte,s lead compound, LB‑100, is being conducted, has been expanded ... Kovach , M.D., the founder and President of Lixte, said ... a single site. Accrual of patients, however, was slower than ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... Dec. 2, 2010 United Seating & Mobility (USM) ... suppliers, is excited to announce today that it has finalized ...   The transaction applies to Fridley, MN serving ... Milwaukee Area, and Appleton, WI; RehabTECH will continue to operate ...
... (OTC Bulletin Board: CDXC ), a leader ... research services, today announced that it has entered into ... to supply analytical reference standards, quality control methods and ... raw materials and finished goods. "With increasing ...
Cached Medicine Technology:ChromaDex Partners With Kappa Bioscience to Provide Quality Control Methods, Tools and Services for Vitamin K2 2
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 Joan ... and keynote speaker at the upcoming 32nd Annual ... ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , shares ... would have gone undetected if she had not followed ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
(Date:1/22/2015)... January 22, 2015 IsoComforter, Inc. has introduced ... with patented IsoTube design to treat specific body parts and ... most progressive and easy to use patented cold therapy machine ... sports related orthopedic and muscle injuries. IsoComforter has become ...
(Date:1/22/2015)... Payday lending practices in four southern states worsen ... to the states that permit them, according to a ... Race and Wealth. , While they generate hundreds of ... the same time substantially depress economic activity, according to ...
(Date:1/22/2015)... As interest in the value of spiritual support as ... Rev. Eric J. Hall , president and CEO of the ... the keynote speaker on January 27 at an international summit ... The conference, “Hope and Resilience: Innovative and Interdisciplinary Spiritual Care,” ...
Breaking Medicine News(10 mins):Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... years ago, the first Ronald McDonald House(R) opened its ... home" for families with seriously ill children. Today, McDonald,s(R) ... celebration to commemorate this important milestone and their long-standing ... , , "For 35 years, local McDonald,s franchisees ...
... For more than 30 years, consumers have benefited from the ... effects of the sun, including sun burn, premature skin aging, ... efficacy of sunscreen products have been thoroughly studied and tested ... is an extensive body of credible scientific research that demonstrates ...
... scientists, patients and members of the biotech industry from around ... unique research center on muscular dystrophy -- the Senator Paul ... , Established last year and based at Boston Biomedical Research ... Center and the only center in the world to focus ...
... Discovery may help explain why disease runs in families, , ... to inherited testicular germ-cell cancer has been identified by scientists ... contributes to our understanding of why testicular germ-cell cancer appears ... said in an agency news release. "The findings may also ...
... published in the July issue of The Journal ... (PET) scans in mice can be used to determine ... working as intended. Researchers successfully used PET and a ... with aggressive breast cancerin breast cancer cells before and ...
... NEW BRUNSWICK, N.J. and DUBLIN, July 2 Johnson & ... (NYSE: ELN ) today announced a definitive agreement ... assets and rights of Elan related to its Alzheimer,s Immunotherapy ... addition, Johnson & Johnson, through its affiliate, will invest $1 ...
Cached Medicine News:Health News:Ronald McDonald House Charities(R) (RMHC(R)) and McDonald's(R) Seek Inspiring Stories Through New 'Share.Give.Hope.' Campaign 2Health News:Ronald McDonald House Charities(R) (RMHC(R)) and McDonald's(R) Seek Inspiring Stories Through New 'Share.Give.Hope.' Campaign 3Health News:Statement by John Bailey, Chief Scientist The Personal Care Products Council, Response to EWG's 2009 Sunscreen Report 2Health News:Statement by John Bailey, Chief Scientist The Personal Care Products Council, Response to EWG's 2009 Sunscreen Report 3Health News:Statement by John Bailey, Chief Scientist The Personal Care Products Council, Response to EWG's 2009 Sunscreen Report 4Health News:Statement by John Bailey, Chief Scientist The Personal Care Products Council, Response to EWG's 2009 Sunscreen Report 5Health News:Successful Beginning for Wellstone Muscular Dystrophy Center at Boston Biomedical Research Institute 2Health News:Another Genetic Link to Testicular Cancer Is Found 2Health News:Study shows PET can measure effectiveness of novel breast cancer treatment 2Health News:Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment 2Health News:Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment 3Health News:Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment 4Health News:Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment 5
... Performance beyond your investment., ,The Centiva/5 Critical ... and time demands of the critical care environment. ... in mind combining a compact size with high ... up valuable space around the patients bed and ...
... Although other treatments for ,ED (e.g. ... used today, ,Vacuum Therapy is ... and their physicians ,because of the very ... should be used as a daily ,exercise ...
... is combining a lightweight mesh material with the ... hernia plug which stands for a high patient ... material is included in Premilene Mesh LP Self-Forming ... for a softer and less bulky Plug Premilene ...
... a mesh plug to treat large or ... hernias and femoralhernias. The self-expanding plug perfectly ... completely. Premilene Mesh Self-Forming Plug is a ... Mesh. The plug corresponds with all properties ...
Medicine Products: